Results 171 to 180 of about 19,810 (255)

Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients?

, 2021
Martyn Caplin
openalex   +1 more source

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors. [PDF]

Pharmaceuticals (Basel)
Leupe H, Cauwenbergh M, Cleeren F, Dekervel J, Verslype C, Deroose CM.   +5 more
europepmc   +1 more source

Peptide receptor radionuclide therapy of neuroendocrine neoplasms using lutetium-177 and yttrium-90 labeled somatostatin analogs: A single center experience in over 1000 patients [PDF]

, 2017
Abhilash Singh, Harshad Kulkarni, Thomas Langbein, Candioti Lehmann, Karin Niepsch, David W.M. Muller, Merten Hommann, Daniel Kaemmerer, Arthur Jochems, Philippe Lambin, Dieter Hörsch, Richard P. Baum   +11 more
openalex   +1 more source

IL-33 as a Marker of Poor Early Response in Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. [PDF]

Int J Mol Sci
Vuleta Nedic K, Gajovic N, Jovanovic I, Jurisevic M, Jovanovic M, Jakovljević S, Popovic B, Djordjevic J, Ignjatovic V, Vukomanovic V.   +9 more
europepmc   +1 more source

Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience. [PDF]

Endocr Oncol
Chow W, Wen I, Mok C, Huang K, Stevenson W, Roach PJ, Bailey DL, Diakos CI, Clarke SJ, Pavlakis N, Chan DL.   +10 more
europepmc   +1 more source

Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years. [PDF]

Theranostics
Zhang J, Mensel B, Baum RP.
europepmc   +1 more source

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors. [PDF]

J Neuroendocrinol
Santo G, di Santo G, Cicone F, Virgolini I.   +3 more
europepmc   +1 more source

SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. [PDF]

Eur J Nucl Med Mol Imaging
Hasenauer N, Müller M, Hänscheid H, Serfling SE, Michalski K, Heinrich M, Polat B, Buck AK, Werner RA, Hartrampf PE.   +9 more
europepmc   +1 more source

The prognostic influence of the proliferative discordance in metastatic pancreatic neuroendocrine carcinoma revealed by peptide receptor radionuclide therapy

, 2017
Nathanaëlle Montanier, Juliette Joubert‐Zakeyh, Caroline Pétorin, Pierre François Montoriol, Salwan Maqdasy, A. Kelly   +5 more
openalex   +1 more source

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma. [PDF]

Mol Imaging Biol
Kunte SC, Wenter VU, Holzgreve A, Sheikh GT, Widjaja L, Gildehaus FJ, Lindner S, Schirrmacher R, Spitzweg C, Auernhammer CJ, Werner RA, Zacherl MJ.   +11 more
europepmc   +1 more source